1sl3: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
In an effort to discover potent, clinically useful thrombin inhibitors, a | In an effort to discover potent, clinically useful thrombin inhibitors, a rapid analogue synthetic approach was used to explore the P(1) region. Various benzylamines were coupled to a pyridine/pyrazinone P(2)-P(3) template. One compound with an o-thiadiazole benzylic substitution was found to have a thrombin K(i) of 0.84 nM. A study of ortho-substituted five-membered-ring heterocycles was undertaken and subsequently demonstrated that the o-triazole and tetrazole rings were optimal. Combination of these potent P(1) aryl heterocycles with a variety of P(2)-P(3) groups produced a compound with an extraordinary thrombin inhibitory activity of 1.4 pM. It is hoped that this potency enhancement in P(1) will allow for more diversification in the P(2)-P(3) region to ultimately address additional pharmacological concerns. | ||
==Disease== | ==Disease== | ||
| Line 17: | Line 17: | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
[[Category: Thrombin]] | [[Category: Thrombin]] | ||
[[Category: Barrow, J | [[Category: Barrow, J C.]] | ||
[[Category: Bohn, D.]] | [[Category: Bohn, D.]] | ||
[[Category: Clayton, F | [[Category: Clayton, F C.]] | ||
[[Category: Cook, J | [[Category: Cook, J J.]] | ||
[[Category: Glass, K | [[Category: Glass, K L.]] | ||
[[Category: Krueger, J | [[Category: Krueger, J A.]] | ||
[[Category: Kuo, L | [[Category: Kuo, L C.]] | ||
[[Category: Lewis, S | [[Category: Lewis, S D.]] | ||
[[Category: Lucas, B | [[Category: Lucas, B J.]] | ||
[[Category: Lundell, G | [[Category: Lundell, G F.]] | ||
[[Category: McMasters, D | [[Category: McMasters, D R.]] | ||
[[Category: Miller-Stein, C.]] | [[Category: Miller-Stein, C.]] | ||
[[Category: Newton, C | [[Category: Newton, C L.]] | ||
[[Category: Pellicore, J | [[Category: Pellicore, J M.]] | ||
[[Category: Pietrak, B | [[Category: Pietrak, B L.]] | ||
[[Category: Rittle, K | [[Category: Rittle, K E.]] | ||
[[Category: Selnick, H | [[Category: Selnick, H G.]] | ||
[[Category: Stauffer, K | [[Category: Stauffer, K J.]] | ||
[[Category: Vacca, J | [[Category: Vacca, J P.]] | ||
[[Category: Williams, P | [[Category: Williams, P D.]] | ||
[[Category: Young, M | [[Category: Young, M B.]] | ||
[[Category: 170]] | [[Category: 170]] | ||
[[Category: thrombin inhibitor complex]] | [[Category: thrombin inhibitor complex]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 15:02:39 2008'' | ||
Revision as of 16:02, 21 February 2008
|
crystal structue of Thrombin in complex with a potent P1 heterocycle-Aryl based inhibitor
OverviewOverview
In an effort to discover potent, clinically useful thrombin inhibitors, a rapid analogue synthetic approach was used to explore the P(1) region. Various benzylamines were coupled to a pyridine/pyrazinone P(2)-P(3) template. One compound with an o-thiadiazole benzylic substitution was found to have a thrombin K(i) of 0.84 nM. A study of ortho-substituted five-membered-ring heterocycles was undertaken and subsequently demonstrated that the o-triazole and tetrazole rings were optimal. Combination of these potent P(1) aryl heterocycles with a variety of P(2)-P(3) groups produced a compound with an extraordinary thrombin inhibitory activity of 1.4 pM. It is hoped that this potency enhancement in P(1) will allow for more diversification in the P(2)-P(3) region to ultimately address additional pharmacological concerns.
DiseaseDisease
Known diseases associated with this structure: Dysprothrombinemia OMIM:[176930], Hyperprothrombinemia OMIM:[176930], Hypoprothrombinemia OMIM:[176930]
About this StructureAbout this Structure
1SL3 is a Single protein structure of sequence from Homo sapiens with as ligand. Active as Thrombin, with EC number 3.4.21.5 Full crystallographic information is available from OCA.
ReferenceReference
Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors., Young MB, Barrow JC, Glass KL, Lundell GF, Newton CL, Pellicore JM, Rittle KE, Selnick HG, Stauffer KJ, Vacca JP, Williams PD, Bohn D, Clayton FC, Cook JJ, Krueger JA, Kuo LC, Lewis SD, Lucas BJ, McMasters DR, Miller-Stein C, Pietrak BL, Wallace AA, White RB, Wong B, Yan Y, Nantermet PG, J Med Chem. 2004 Jun 3;47(12):2995-3008. PMID:15163182
Page seeded by OCA on Thu Feb 21 15:02:39 2008
Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)
OCA- Pages with broken file links
- Homo sapiens
- Single protein
- Thrombin
- Barrow, J C.
- Bohn, D.
- Clayton, F C.
- Cook, J J.
- Glass, K L.
- Krueger, J A.
- Kuo, L C.
- Lewis, S D.
- Lucas, B J.
- Lundell, G F.
- McMasters, D R.
- Miller-Stein, C.
- Newton, C L.
- Pellicore, J M.
- Pietrak, B L.
- Rittle, K E.
- Selnick, H G.
- Stauffer, K J.
- Vacca, J P.
- Williams, P D.
- Young, M B.
- 170
- Thrombin inhibitor complex